查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179873

2023-2030 年全球胰岛素抵抗市场

Global Insulin Resistance Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期内 (2023-2030)，全球胰岛素抵抗市场规模预计将以 4.2% 的复合年增长率增长。

胰岛素抵抗是对正常胰岛素水平异常缓慢的生理反应。 胰岛素抵抗是肌肉、脂肪和肝细胞对胰岛素反应不佳，不能利用血液中的葡萄糖作为能量的一种状态。 结果，胰腺开始产生更多的胰岛素。 血糖水平随时间上升。 2 型糖尿病、胆固醇、血压和肥胖是胰岛素抵抗综合症的例子。

市场动态

推动全球胰岛素抵抗市场的主要因素是久坐不动的生活方式增加和糖尿病患病率上升。 保险报销和其他与价格相关的政府法规也有望推动市场，而医疗保健行业的增长和公众对最先进医疗程序的了解的增加预计将推动市场。

久坐不动的生活方式不断扩大，糖尿病患病率不断上升

由于久坐不动的生活方式的增加和糖尿病患病率的上升，胰岛素抵抗市场正在扩大。 由于人口老龄化、久坐不动的生活方式增加和肥胖增加，预计胰岛素抵抗患者会增加。 此外，久坐不动的生活方式的建立和身体活动的减少也越来越受到关注。 葡萄糖耐量测试包括在服用一剂葡萄糖后采集血液，以评估葡萄糖从体内清除的速度。 它通常用于检查糖尿病、胰岛素抵抗、β 细胞活性降低、反应性低血糖症、肢端肥大症和其他不太常见的碳水化合物代谢疾病。

根据国际糖尿病联合会的数据，到 2021 年，估计将有 5.37 亿成年人（20-79 岁）患有糖尿病。 另据估计，2030 年将有 6.43 亿人患有糖尿病，2045 年将有 7.83 亿人患糖尿病，其中四分之三的人生活在低收入和中等收入国家。 近二分之一的成年人（2.4 亿）患有糖尿病。 该市场受到全球糖尿病患病率上升的推动。

有限的药物选择和缺乏有关胰岛素抵抗的信息预计会阻碍市场增长。

可用药物的稀缺和对胰岛素抵抗知识的缺乏是预计阻碍胰岛素抵抗市场增长的一些因素。 此外，该行业在发展中国家和新兴国家需要更多的救赎。

COVID-19 影响分析

疫情对全球金融预期、运营和危机应对策略产生了负面影响。 患有某些潜在疾病的个体可能因 COVID-19 而患重病的风险增加。 例子包括糖尿病、心脏病、肥胖症和慢性肾病。 CDC 的某些研究发现，2 型糖尿病患者患 COVID-19 相关严重疾病的风险增加。 COVID-19 大流行提高了可及性和可负担性的优先级，这也影响了糖尿病患者的发展战略。

许多在美国市场运营的製药公司已经启动了计划，以帮助患者在大流行期间获得胰岛素。 由于 COVID-19 流行病的社会经济影响，许多醣尿病患者可能无法获得医疗保健。 随着对胰岛素和抗糖尿病药物的需求增加，製药公司将有更多机会为糖尿病患者创造新颖且更容易获得的治疗方法。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 久坐不动的生活方式增加，糖尿病患病率增加
      • 有关保险报销和定价的政府法规也在推动市场发展
    • 约束因素
      • 缺乏药物选择，缺乏关于胰岛素抵抗的信息
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章药物类别

  • 双胍类
  • 胰高血糖素样□ 1 (GLP-1) 受体激动剂
  • 浓缩胰岛素製剂
  • 钠葡萄糖协同转运蛋白 2 (SGLT2) 抑製剂
  • 二□基□□ 4 (DPP-4) 抑製剂
  • 其他

第 8 章按药物类型分类

  • 品牌
  • 仿製药

第 9 章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第12章公司简介

  • Glenmark Pharmaceuticals
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Merck & Co.
  • Nova Nordisk
  • Teva Pharmaceuticals
  • Sanofi
  • GlaxoSmithKline
  • Mylan.

第 13 章全球胰岛素抵抗市场-DataM

简介目录
Product Code: DMPH23

Market Overview

The Global Insulin Resistance Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.2% during the forecast period (2023-2030).

Insulin resistance is an abnormally slow physiologic reaction to normal insulin concentrations. When cells in the muscles, fat, and liver do not respond to insulin well and cannot utilize glucose from the blood for energy, this condition is known as insulin resistance. The pancreas produces more insulin as a result. Blood sugar levels rise over time. Type 2 diabetes, cholesterol, blood pressure, and obesity are just a few of the conditions that are a part of insulin resistance syndrome.

Market Dynamics

The major factors driving the global insulin resistance market are the growing sedentary lifestyle and expanding diabetes prevalence, the market will also be driven by reimbursement and other pricing-related government regulations, and the growing healthcare sector and increased public knowledge of cutting-edge medical procedures will propel the market.

Growing sedentary lifestyle and expanding diabetes prevalence.

The market for insulin resistance is expanding as a result of rising sedentary lifestyles and rising diabetes prevalence. Patients with insulin resistance are expected to increase due to an aging population, an increase in sedentary lifestyles, and an increase in obesity incidence. Concerns are increased by sedentary lifestyle adoption and a decline in physical activity. In the glucose tolerance test, blood samples are taken after glucose is administered to assess how rapidly it is eliminated from the body. Typically, the test is used to check for diabetes, insulin resistance, decreased beta cell activity, reactive hypoglycemia, acromegaly, and other less common abnormalities of carbohydrate metabolism.

According to International Diabetes Federation estimates that 537 million adults (20-79 years old) will have diabetes by 2021. By 2030, there will be 643 million people worldwide living with diabetes, and by 2045, there will be 783 million; 3 in 4 individuals with diabetes reside in low- and middle-income nations. Adults with diabetes make up almost one in two people (240 million). The market is driven by the rising prevalence of diabetes globally.

Limited pharmaceutical choices and lack of information on insulin resistance is expected to hamper the market's growth.

The availability of few medications and the lack of knowledge about insulin resistance are some of the factors expected to hinder the growth of the insulin resistance market. Additionally, the industry needs more reimbursement in developing and rising nations.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. An increased risk of developing a serious disease from COVID-19 may exist in individuals with specific underlying medical disorders. Diabetes, cardiac issues, obesity, and chronic kidney disease are some ailments. According to a CDC specific study, type 2 diabetes patients had a higher risk of developing severe COVID-19-related illnesses, according to the CDC. Accessibility and affordability have increased in priority due to the COVID-19 pandemic, which also affected diabetic developer strategies.

To assist patients in getting insulin during the pandemic, numerous pharmaceutical companies operating in the US market have publicly publicized programs. When many diabetes patients may not have access to healthcare due to the socio-economic impact of the COVID-19 epidemic. Drug manufacturers have a greater chance to produce novel and more approachable therapies for the diabetic population due to the increased demand for insulin and anti-diabetics.

Segment Analysis

Concentrated insulin products of Insulin resistance the segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Over the past few years, there have been more concentrated insulin products available in the US to treat diabetic patients. These medications may give patients options to improve glycemic control with treatment regimens that may increase their adherence to therapy since they contain more units of insulin per milliliter than typical U-100 insulins. All concentrated insulins are offered in distinctive prefilled pen devices that make it easy to identify the product and administer doses precisely.

Recent developments in concentrated insulins (exceeding 100 units/mL) and specialized equipment have given persons with diabetes new treatment choices for basal and prandial insulin supplementation. The concentrations of concentrated insulin formulations range from 2-fold (insulin lispro 200 units/mL), which has a fast-acting prandial effect, to 5-fold (human regular insulin 500 units/mL), which has basal and short-acting prandial activities. Degludec 200 units/mL and glargine 300 units/mL are two long-acting basal insulins. Concentrated insulins were created with the intention of simplifying the administration of insulin by lowering the volume and frequency of injections and, in certain cases, by utilizing modified pharmacokinetic and pharmacodynamic features. The market is driven by the development of the product and its use.

Geographical Analysis

North America holds the largest market share in the global Insulin resistance market.

Nearly 40% of young adults without diabetes, according to research from the University of Alabama at Birmingham in 2021, have insulin resistance, a disease in which the body does not respond to insulin as it should and cannot use blood glucose for energy. In the United States, where nearly 50% of the earnings for the manufacturers of insulin come from within the nation, the cost aspect is the biggest concern.

Under the direction of the Institute of Nutrition, Metabolism, and Diabetes, the Canadian Institutes of Health Research is funding cutting-edge research into diabetes (CIHR-INMD). 100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes is a significant initiative that the Institute launched in 2019 to increase funding for Canadian researchers so they can work with collaborators to find novel approaches to preventing and treating diabetes and its complications. The region's market growth is primarily influenced by powerful market rivals, increasing healthcare GDP spending, and improved government reimbursement for insulin treatment.

Competitive Landscape

The insulin resistance market is moderately competitive with local and global companies' presence Glenmark Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Nova Nordisk, Teva Pharmaceuticals, Sanofi, GlaxoSmithKline, Mylan and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in October 2022, Glenmark Pharmaceuticals announced the introduction of Thiazolidinedione Lobeglitazone for the treatment of type 2 diabetes in adults. According to a statement from Glenmark Pharmaceuticals, there is a high frequency of insulin resistance among Indians, making LOBG an appealing treatment option for treating insulin-resistant diabetic patients with uncontrolled Type 2 diabetes

Glenmark Pharmaceuticals.

Overview: Glenmark Pharmaceuticals Ltd. (Glenmark) 's primary objective is developing novel chemical entities (NCEs). The company creates and sells both branded and generic formulations. Oncology, dermatology, and respiratory are just a few therapeutic specialties covered by the company's formulations division. Additionally, it is used in numerous therapeutic contexts, including oral contraceptives, diabetes, and cardiovascular conditions. The firm produces and distributes active medicinal components (APIs). Glenmark has production sites in the Czech Republic, the United States, Argentina, and India.

Product Portfolio:

LOBG: Thiazolidinedione Drug called lobeglitazone that increases insulin sensitivity The anti-diabetic drug will be offered for sale under the trade name LOBG . It has 0.5 mg of lobeglitazone and should be taken one daily as directed. LOBG is a desirable medical alternative for patients with Type 2 diabetes who are insulin resistant.

The global Insulin resistance market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing sedentary lifestyle and expanding diabetes prevalence
      • 4.1.1.2. The market will also be driven by reimbursement and other pricing-related government regulations
    • 4.1.2. Restraints:
      • 4.1.2.1. Limited pharmaceutical choices and lack of information on insulin resistance
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Biguanides
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Glucagon-like Peptide 1 (GLP-1) Receptor Agonists
  • 7.4. Concentrated Insulin Products
  • 7.5. Sodium-glucose cotransporter 2 (SGLT2) inhibitors
  • 7.6. Dipeptidyl peptidase-4 (DPP-4) inhibitor
  • 7.7. Others

8. By Drug Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 8.1.2. Market Attractiveness Index, By Drug Type
  • 8.2. Branded
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Generics

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size AnalysisUS$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Glenmark Pharmaceuticals
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AstraZeneca
  • 12.3. Bristol-Myers Squibb
  • 12.4. Eli Lilly and Company
  • 12.5. Merck & Co.
  • 12.6. Nova Nordisk
  • 12.7. Teva Pharmaceuticals
  • 12.8. Sanofi
  • 12.9. GlaxoSmithKline
  • 12.10. Mylan.

LIST NOT EXHAUSTIVE

13. Global Insulin resistance Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Application
  • 13.3. Contact Us